Lyra therapeutics presents positive data from lantern phase 2 study of lyr-210 for treatment of chronic rhinosinusitis at cosm 2022

Lyr-210 provided up to 24 weeks of clinically meaningful global symptom improvement in crs patients lyr-210 achieved significant improvement in each crs symptom subdomain of the snot-22 compared to control lyr-210 may improve mental and physical health and quality of life of crs patients watertown, mass. , april 29, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today is presenting additional, new data from its lantern phase 2 study of lyr-210 in adult patients with chronic rhinosinusitis (crs) at the 2022 combined otolaryngology spring meetings (cosm) being held april 27 – may 1, 2022 in dallas, texas.
LYRA Ratings Summary
LYRA Quant Ranking